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Purpose: To analyze the state of the science of community-associated
methicillin-resistant Staphylococcus aureus (CA-MRSA) in the United States to
support the integration of current knowledge for primary care nurse practi-
tioners’ (PCNP) practice.
Data sources: Published research limited to U.S. studies in MEDLINE,
CINAHL, and Cochrane Review from 1950 to the week of September 4, 2008.
Investigations were identified through electronic search engines and databases.
Manual searches were done of hard copy references in journal articles. Cita-
tions and reference lists for English language research studies of CA-MRSA in
the United States were reviewed to identify additional research that fit evalu-
ation criteria for this analysis.
Conclusions: Until the late 1990s, healthcare-associated MRSA (HA-MRSA)
was the predominant cause of serious infections. Recently, CA-MRSA has
caused infections in previously healthy nonhospitalized people. Major demo-
graphic and epidemiological differences exist between the two types of resis-
tant bacteria; the emergence of CA-MRSA suggests new implications for pri-
mary care.
Implications for practice: PCNPs will undoubtedly treat MRSA infections
and need a comprehensive understanding of the pathogenicity, diagnosis, and
management of CA-MRSA to ensure expedient and appropriate treatment.
This will help to prevent invasive disease as a result of improperly treated in-
fections.
Fleming’s discovery of penicillin in 1929 heralded a new
method for treatment of Staphylococcus aureus (SA) infec-
tions, the most common cause of postsurgical and soft
tissue infections in the United States. Although penicillin
was effective, it was expensive to produce and was not
widely used until the 1940s when available mass produc-
tion methods of penicillin lowered the cost, allowing the
drug to be used to treat both civilians and wounded sol-
diers during World War II.
However, by the 1950s resistance to the treatment
emerged as a result of plasmid-mediated penicillinase
production by some strains of SA. In response to the
penicillin resistance, methicillin was introduced for SA
treatment in 1959. However, within a year, methicillin-
resistant SA (MRSA) developed in the United Kingdom
(Halem, Trent, Green, & Kerdel, 2006; Jevons, 1961).
By the 1970s, healthcare-associated methicillin-resistant
SA (HA-MRSA), formerly known as hospital acquired
MRSA, was endemic in many U.S. hospitals and extended
care facility (ECF) residents, primarily affecting the el-
derly and the chronically ill (Centers for Disease Control
and Prevention [CDC], 2006a).
It soon appeared that methicillin resistance was not
limited to healthcare facilities and geriatric populations.
In 1981 in Detroit, Michigan, MRSA was identified
in community-dwelling intravenous drug users (IVDUs;
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CDC, 1981). Healthcare providers became more con-
cerned when community-associated methicillin-resistant
SA (CA-MRSA) infections caused the deaths of four chil-
dren in the United States in 1999 (CDC, 1999). The pub-
lic became acutely aware of the organism when USA To-
day reported an MRSA infection outbreak among the St.
Louis Rams (Milhoces, 2005). Since then, media reports
have increased public awareness of CA-MRSA. In addi-
tion, community-associated strains of MRSA bacteria are
now the cause of many serious healthcare-associated in-
fections (Gonzalez et al., 2006).
Although not fully understood, the resistance of SA
and Staphylococcus epidermis (SE) to antibiotics may be at-
tributed to the increasing use of antibiotics. This antibiotic
use, coupled with the fact that beta-lactam antibiotics are
excreted by sweat, can stimulate the staphylococci bacte-
ria normally on the skin to develop beta-lactam resistance
(Holby, Pers, Johansen, and the Copenhagen study group
of Antibiotics in Sweat, 2000). Such constantly evolving
knowledge about CA-MRSA presents a challenge to ad-
vanced practice nurses (APN) who provide inpatient and
outpatient care. Obtaining the most current knowledge
about the prevention of CA-MRSA disease transmission is
a vital step toward reducing suffering, minimizing health-
care costs, and avoiding loss in productivity.
Although much has been published about the treat-
ment and management of HA-MRSA, a comprehensive
overview of the state of the science of CA-MRSA and the
implications for patient care by primary care nurse prac-
titioners (PCNPs) has received less attention. Therefore,
this article describes CA-MRSA pathophysiology, treat-
ment, and management in the United States and impli-
cations for PCNPs and MRSA treatment.
Epidemiology
Detailed information on the studies of incidence and
prevalence of MRSA is included in Table S1. Studies have
focused on incidence and prevalence of CA- and HA-
MRSA in various locations across the United States. The
following section is a summary of the studies reviewed.
SA and MRSA colonization
Two major population-based studies conducted in the
United States on the National Health and Nutrition Ex-
amination Survey (NHANES) data from 2001 to 2002 de-
termined SA and MRSA colonization prevalence rates.
Both authors (Graham, Lin, & Larson, 2006; Kuehnert
et al., 2006) published independently analyzed results in
2006 with similar conclusions: in 2001–2002 just over
30% of the U.S. noninstitutionalized population was col-
onized with SA, while less than 1% were colonized with
MRSA. However, since 2002, incidence and prevalence
of both HA-MRSA and CA-MRSA have increased dra-
matically (Bartels, Boye, Larsen, Skove, & Westh, 2007;
Stevenson, Searle, Stoddard, & Samore, 2005; Vande-
nesch et al., 2003).
MRSA and CA-MRSA in health care
In the United States, 94,360 invasive MRSA infections
occurred in 2005, causing 18,650 deaths. Of the 94,360
infections, 75.2% were bacteremias, 26.6% of these bac-
teremias were hospital onset, while 7% specifically repre-
sented CA-MRSA invasive disease (Klevens et al., 2007).
The incidence of MRSA infections in healthcare settings
is as high as 40% (Kiran et al., 2006). The 1992–2002 Na-
tional Nosocomial Infection Surveillance (NNIS) reported
that MRSA accounted for more than 53% of all hospital
SA isolates (NNIS, 2002).
HA-MRSA infection and colonization
A national point-prevalence study conducted within
U.S. healthcare facilities during October and November
2006 found that 46 out of every 1000 hospitalized pa-
tients were either colonized or infected with MRSA, a rate
eight to 11 times greater than previously estimated (CDC,
2007a). Theoretically, HA-MRSA spreads into the com-
munity when hospitalized patients colonized with HA-
MRSA are discharged (Salgado, Farr, & Calfee, 2003).
Therefore, HA-MRSA is increasing both in healthcare set-
tings and in the community.
CA-MRSA infection in health care
CA-MRSA is epidemic in many regions of the United
States (Purcell & Fergie, 2005). The incidence of CA-
MRSA reported in both inpatient and outpatient settings
vary. For example, in a population-based surveillance,
Baltimore CA-MRSA disease incidence was 18/100,000,
while CA-MRSA isolate incidence in Atlanta was
24.7/100,000 (Fridkin et al., 2005). In Chicago, CA-
MRSA hospital infection incidence increased over a 5-
year period from 24/100,000 to 164.2/100,000 (Hota
et al., 2007). Approximately 60% of all U.S. emergency
department SA skin and soft tissue infections (SSTIs) are
caused by MRSA (Moran et al., 2006); however, primary
care settings, especially pediatric settings, are also experi-
encing increases in MRSA skin infections (Hersh et al.,
2009; Hinckley & Allen, 2008). Because CA-MRSA is
identified in healthcare facilities, experts predict that this
trend could eventually lead to increased severity of CA-
MRSA infections among hospitalized patients (D’Agata,
Webb, Horn, Moellering, & Ruan, 2009).
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CA-MRSA colonization among outpatients and in
the community
The prevalence of CA-MRSA varies. An outpatient
colonization prevalence study found that 12.3% of all
SA isolates were MRSA (Jernigan, Pullen, Partin, &
Jarvis, 2003). A more recent outpatient infection preva-
lence study compared community-associated methicillin-
sensitive SA (CA-MSSA) and CA-MRSA infections in
four hospital outpatient settings (William Beaumont, MI;
Henry Ford, MI; Pittsburg Veterans Administration Med-
ical Center, PA; and Rush University Medical Center, IL)
and found the overall prevalence of MRSA to be 26.7% of
all SA infections (Davis et al., 2007). A population-based
CA-MRSA prevalence study conducted among the ur-
ban poor identified a 2.8% CA-MRSA colonization preva-
lence (Charlebois et al., 2002).
Population risk factors
CA-MRSA has been described in people who are often
at risk of other infections because of living situations, eco-
nomic and/or health disparities, or life style. For example,
military personnel (Ellis, Hospenthal, Dooley, Paula, &
Clinton, 2004), prisoners (CDC, 2003), the homeless, the
urban poor, and residents of public housing (Charlebois
et al., 2002), men who have sex with men (MSM) (Iyer &
Jones, 2004; Lee et al., 2005), and IVDUs are considered
to be among such high-risk groups. Transmission may
also occur in athletic settings or in daycare through the
sharing of personal items, such as toys, towels, and ra-
zors (Cohen, 2005), or living in close quarters such as in
military settings or prison (Ellis et al., 2004; CDC, 2003).
It is likely that CA-MRSA transmission is related to
skin-to-skin contact, lifestyle—such as IVDU or metham-
phetamine use (Cohen et al., 2007; Miller et al., 2005)—
and poor hygiene (Calfee et al., 2003; Dinusha, Auld,
& Mermel, 2004). Higher incidences have also been de-
scribed in African Americans (Fridkin et al., 2005; Ochoa,
Mohr, Wanger, Murphy, & Heresi, 2005), Native Ameri-
cans (Cookson, 2000; Groom et al., 2001; Ofner-Agostini,
Simore, Bryce, McGeer, & Paton, 2006), and children
(Herold et al., 2007), particularly children who attend
daycare (Dinusha et al., 2004; Fergie & Purcell, 2001;
Lee et al., 2004). However, it is unclear whether it is the
physical settings or independent risk factors of individu-
als or specific populations that are the causes for higher
incidence.
Antibiotic resistance and microbial genetics
Because of their genotypic differences, HA-MRSA and
CA-MRSA do not manifest the same clinical virulence
patterns or antibiotic resistance. The differences are
caused by genetic factors that affect patient illness, an-
tibiotic resistance, and treatment.
All SA bacteria have a mobile genetic element known
as Staphylococcal cassette chromosome (SCCmec). A sub-
set of a larger SCCmec gene, the mecA gene and its varia-
tion determines the antibiotic differences between HA-
MRSA and CA-MRSA bacteria. Although both possess
mecA genes, there are differences in the genetic sequence
that create variances in the bacteria’s resistance levels
(Donnio, Prendy, Lerestif, Avril, & Lafforgue, 2004). Con-
sequently, mecA gene determination is one method by
which CA-MRSA is differentiated from HA-MRSA (Bell,
2008).
Further, beta-lactam resistance occurs as a result of
the SA mecA gene production of the penicillin bind-
ing peptide (PBP2a), which decreases bacterial affinity
to beta-lactams (Donnio et al., 2004). Therefore, each
organism will require different treatment. For example,
HA-MRSA is only sensitive to certain antibiotics and
should be treated with vancomycin, linozelid, and dap-
tomycin (Loffler & MacDougall, 2007). On the other
hand, CA-MRSA exhibits more susceptibility to addi-
tional classes of antibiotics such as tetracycline (doxy-
cline), trimethoprim-sulfamethoxazole (TMX/SMP), gen-
tamycin, and clindamycin (Loffler & MacDougall, 2007)
as a result of the type of SCC mecA gene found in
CA-MRSA.
CA-MRSA antibiotic resistance is increasing. Emer-
gence of resistance to clindamycin during treatment
for CA-MRSA (inducible resistance) is described in sev-
eral published reports (Hulten et al., 2006; Martinez-
Aguilar et al., 2004). However, certain types of
CA-MRSA infections are less resistant and therefore eas-
ier to treat. For example, pediatric CA-MRSA isolates
were significantly less resistant than were adult isolates
to clindamycin, ciprofloxin, gentamycin, and tetracycline
(David et al., 2006). Adult CA-MRSA infections should
rarely be treated with these antibiotics, and providers
should carefully monitor MRSA antibiotic susceptibil-
ity patterns for pediatric and adult patients within the
community.
The CA-MRSA SCC mec gene complex differs from
the HA-MRSA mec gene complex in yet another way,
the presence or absence of toxin genes (Naimi et al.,
2003). Nearly all strains of SA secrete substances that
convert host tissues into the nutrients needed for bac-
terial growth. However, some strains produce additional
substances, known as toxins, that are responsible for se-
rious clinical manifestations such as necrotizing disease
and aggressive tissue destruction.
Toxin genes are present in CA-MRSA worldwide
(Wannet et al., 2004). These genes are considered
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key virulence determinants factors in CA-MRSA disease
(Gonzolez et al., 2005; Wang et al., 2007). CA-MRSA
is characterized by a toxin, known as Panton-Valentine
leukocidin (PVL), which causes leukocyte destruction,
tissue necrosis, and complicated, virulent infections such
as necrotizing myositis, faciitis empyema, septic emboli,
and pneumonia (Boubaker et al., 2008; Gonzalez et al.,
2005; Miller et al., 2005). Treatment for CA-MRSA pneu-
monia is different from community-onset pneumonia
as a result of other organisms because it is necrotizing,
producing hemoptysis, and lung cavitation and must be
treated with a toxin-suppressing antibiotic, such as clin-
damycin (Hidron, Low, Honig, & Blumberg, 2009). The
presence of toxin genes causes CA-MRSA infections to
be more aggressive and invasive in healthier patients as
compared with patients affected by HA-MRSA.
In addition, toxin genes have been found worldwide
in both CA-MSSA and CA-MRSA infections (Vandenesch
et al., 2003). One strain of CA-MRSA is nearly identi-
cal to a form of SA that caused a pandemic in 1950s
(Robinson et al., 2005); therefore, CA-MRSA may not
be a new strain but may represent reemergence of older
strains of SA. Contrary to popular belief, microbiologi-
cally, CA-MRSA bacterium is more like CA-MSSA than
like HA-MRSA (Sattler, Mason, & Kaplan, 2002).
Both CA-MSSA and CA-MRSA infections exhibit very
similar clinical symptoms such as abscesses, cellulitis, fu-
runcles, and both types of community-associated SA are
more invasive and virulent than HA-MRSA infections
(Miller et al., 2007), causing serious disease in healthier,
younger age groups (Robinson et al., 2005). HA-MRSA
does not present as necrotizing disease but rather mani-
fests instead as chronic wounds, decubitus ulcers, pneu-
monia, urinary tract infections, and bacteremia (Boyle-
Vavra & Daum, 2007; Boyle-Vers, Ereshefsy, Wang, &
Daum, 2005; Buescher, 2005; Zaoutis et al., 2006).
Finally, the smaller CA-MRSA mec gene is more mo-
bile and probably more transmissible between host bac-
teria. This characteristic may enhance the spread of
the organism between individuals because the smaller
CA-MRSA SCCmecA gene allows mobile genetic ele-
ments (DNA) within CA-MRSA to move quickly and
easily between other SA chromosomes (Carleton, Diep,
Charlebois, Sensabaugh, & Perdreau-Remington, 2004).
Although CA-MRSA may be easier to treat, CA-MRSA is
also more easily spread than is HA-MRSA.
Patient care aspects
Infection
CA-MRSA most often manifests as SSTIs. Like MSSA
SSTIs, CA-MRSA frequently occurs as abscess(es) (Pur-
cell & Fergie, 2005), furuncles, and carbuncles (Fridkin
et al., 2005; Micek, Dunne, & Kollef, 2005; Moran, Amii,
Abrahamian, & Talan, 2005). These can occur at single
or multiple sites and are accompanied by signs and symp-
toms of infection such as pain, fever, and malaise. In addi-
tion, patients may present with other CA-MRSA draining
manifestations, such as persistent acute otitis media with
or without ottorhea. In these cases, culturing of drainage
before initiating treatment is imperative. The appearance
of the infection provides few clues about the infecting
organism.
Diagnosing and treating CA-MRSA infection
Limited information exists on specific treatment of CA-
MRSA infections, as opposed to other soft tissue infec-
tions. Instead, many experts encourage treating all SSTI
in the same way until cultures can identify the infect-
ing organism. For example, regardless of the suspected
organism, some experts suggest that biopsy and culture
of the advancing edge of induration or cellulitis should
be performed for organism identification (IDPH, 2008;
Winland-Brown, Porter, & Leik, 2007) or a needle aspira-
tion for fluid culture should be considered (CDC, 2006b).
It is important to understand that the national recom-
mendations help to guide practice.
In its publication, Guidelines for SSTIs, The Infectious
Diseases Society of America (IDSA) recommends incision
and drainage (I&D) of purulence and application of heat
as the most effective treatment of abscesses regardless
of the infecting organism (Stevens et al., 2005). Cultur-
ing the drainage before initiating treatment is imperative
to verify the pathogen in any infection (Al-Shawwa &
Wegner, 2005; Bell, 2008; CDC, 2006b). Antibiotic man-
agement of CA-MRSA is different from infections caused
by HA-MRSA; therefore, it is important to differentiate
the organism through culture and susceptibility confir-
mation to determine whether CA-MRSA is susceptible to
less costly antimicrobials and leave more expensive an-
tibiotics (linazelid, vancomycin, or daptomycin) as last re-
sorts (Loffler & MacDougall, 2007).
Empiric treatment of CA-MRSA is recommended while
waiting for confirmation through culture, regardless of
where the patient presents for treatment. As a result of
increased awareness, many outpatient settings are be-
ginning to practice current recommendations. Although
considerable variations exist in the treatment patterns of
MRSA (Conly et al., 2003), recent primary care recom-
mendations emphasize I&D and culturing drainage as a
standard of practice in outpatient clinics, emergency de-
partments, and primary care offices (Hersh et al., 2009;
Moran et al., 2006). Incision and drainage of abscesses
that are less than 5 cm can resolve the infection without
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Table 1 Treatment of CA-MRSA
Immunocompetent afebrile with abscesses Immunocompetent febrile∗ with abscesses
Immunocompromised∗∗ and/or bacteremia,
endocarditis, septic shock, or
osteomyolitis, may require hospitalization
I&D to verify pathogen I&D to verify pathogen Infectious disease consultation
Hot packs Hot packs Treat with: IV vancomycin∗∗∗ 1000 mg every
In lesion(s) >5 cm treat with: In lesion(s) >5 cm treat with: 12 h OR daptomycin 6 mg/kg IV every 24 h.
Two∗ trimethoprim/sulfamethoxazole
(TMP/SMX) double strength (DS) twice daily OR
doxycycline or minocycline 100 mg × 10–14
days
Two∗ TMP/SMX DS twice daily × 10–14 days
with or without rifampin 300 mg twice daily or
600 mg once daily OR linozolid 600 mg orally or
intravenously (IV) twice daily or one dose of
dalbavancin 1000 mg IV
∗Febrile-acute onset of temperature >101.3◦F (38.5◦C), associated with signs and symptoms of bacterial infection (Porter, Jones, Winland-Brown, 2007)
∗Treatment failures have been reported when using one TMP/SMX DS bid (Iyer & Jones, 2004; Cenizal et al., 2007).
∗∗Some types of immunocompromised patients are cancer patients undergoing chemotherapy, patients on chronic steroid use, transplant patients,
HIV-positive patients, splenectomy patients, and diabetic patients. Although many of these types of patients will respond to I&D alone or with oral
CA-MRSA specific antibiotics, it may be necessary for inpatient treatment.
∗∗∗The IDSA guidelines for (2005) suggest dosing vancomycin at 30 mg/kg in two divided doses or daptomycin 4 mg/kg every 24 h for adults (Stevens
et al., 2005). It is imperative to monitor peak and trough levels and creatinine clearance levels in patients undergoing vancomycin therapy.
antibiotics, including those caused by CA-MRSA (Daum,
2007; Rejendran et al., 2007), or when an antibiotic, such
as a beta-lactam, is used empirically (Dooley, Barnes,
Hepburn, & Baum, 2006). Therefore, I&D rather than
antibiotic use, is the first line of treatment for localized
uncomplicated CA-MRSA skin infections (Miller et al.,
2007). Other treatment after incision includes the use of
hot packs on the infection site as well as patient education
about proper skin hygiene (Stevens et al., 2005).
Uncomplicated CA-MRSA SSTI infections are easily
managed (Zafar et al., 2007). As already mentioned,
these sites respond well to I&D. Still severe morbidity or
mortality can occur if the infection is not appropriately
treated in a timely manner (Marcinak & Frank, 2003;
Micek et al., 2005; Rihn et al., 2005). Unlike local SSTI,
invasive CA-MRSA infections can be difficult to eradi-
cate and may result in significant mortality (Kiran et al.,
2006; Klevens et al., 2007). Consequently, serious CA-
MRSA infections should be referred to an infectious dis-
ease expert for management; they will likely need treat-
ment with intravenous vancomycin (Dooley et al., 2006).
Although the actual number of invasive CA-MRSA in-
fections within healthcare settings is low, approximately
13.7% (Klevens et al., 2007), invasive CA-MRSA infec-
tions in the healthcare settings are on the rise (Gonza-
lez et al., 2006; Maree, Daum, Boyle-Vavra, Matayoshi,
& Miller, 2007).
Antibiotic management
Current recommendations from the CDC (2007b) and
The Sanford Guide to Antimicrobial Therapy 2008, 38th edition
(Gilbert, Moellering, Eliopoulos, & Sande, 2008) for out-
patient treatment of CA-MRSA include a step manage-
ment approach depending on the seriousness of the infec-
tion, patient symptoms, and the underlying condition of
the patient. The CDC recommendations for the treatment
of CA-MRSA are guidelines often used by practition-
ers. However, The Sanford Guide to Antimicrobial Therapy,
which incorporates both national standards and rapidly
emerging resistance patterns, is updated and released an-
nually and thus, may provide more current treatment
guidelines. The 2008 recommendations from The Sanford
Guide to Antimicrobial Therapy 2008, 38th edition for treat-
ment of CA-MRSA include the following (see Table 1 for
more detail):
 Outpatient treatment for immunocompetent,
afebrile patients with abscesses includes application
of hot packs and in abscesses greater than 5 cm,
antibiotic treatment with two oral TMP/SMX
double strength (DS) twice daily or doxycycline
or minocycline 100 mg twice daily for 10–14 days
(Gilbert et al., 2008).
 Outpatient treatment for CA-MRSA abscesses, im-
munocompetent, febrile patients would include hot
packs as well as two oral TMP/SMX DS twice daily
for 10–14 days with or without rifampin 300 mg
twice daily or 600 mg once daily or linozolid 600
mg orally or intravenously (IV) twice daily or one
dose of dalbavancin 1000 mg IV (Gilbert et al.,
2008).
 Any patients more serious than this (e.g., pa-
tients who are immunocompromised, or have
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bacteremia, endocarditis, septic shock, or
osteomyolitis) may require hospitalization, in-
fectious disease consultation, and IV vancomycin
1000 mg every 12 h if no impairment in renal
function or daptomycin 6 mg/kg IV (Gilbert et al.,
2008; Rybak et al., 2009).
Patients allergic to sulfonamides should be treated with
doxycycline or minocycline with rifampin (Gilbert et al.,
2008). Finally, because of the potential for inducible re-
sistance when used as monotherapy, rifampin should
never be used alone to treat MRSA (Bubacz, 2007; CDC,
2006b).
Colonization and decolonization
While high levels of microbes are present in active in-
fection, colonization indicates that microbes are present
but in low levels that do not produce illness. HA-MRSA
and CA-MRSA colonization can be detected most fre-
quently in nasal passages (Kenner et al., 2003; Kuehnert
et al., 2006), axilla, groin, perineum, and rectum (Eveil-
lard, Lassence, Barnaud, Ricard, & Joly-Guillou, 2006).
Even though colonization does not represent infec-
tion or active disease, colonization with CA-MRSA in
healthy individuals can later predispose these individu-
als to CA-MRSA infections (Datta & Huang, 2008; Zaoutis
et al., 2006). Further, transmission of CA-MRSA to oth-
ers and environmental contamination can occur in both
the infected and colonized patient. The use of antibiotics
and antimicrobial cleansing agents to eradicate CA-MRSA
from an individual and/or environment, also known as
decolonization, has limited efficacy because many indi-
viduals may recolonize in less than a year (Simor et al.,
2007). Efficient decolonization can be difficult and ex-
pensive to implement; therefore, it may be impractical as
a control strategy.
Control of transmission
The CDC guidelines (2006) for infection prevention and
control of CA-MRSA are primarily applicable to health-
care settings. Although there are contact precaution
recommendations for prevention of transmission of CA-
MRSA within the community that emphasize hand hy-
giene, wound coverage, and environmental cleaning
(CDC, 2008), contact isolation recommendations for the
prevention of MRSA transmission by restricting patients
from public encounters within community settings do not
exist.
Research on other methods of control and detection
has just begun. Therefore, until further research delin-
eates specific guidelines, transmission management of
CA-MRSA in the primary care setting should include
basic hygiene measures; hand washing, containment of
drainage, proper disposal of contaminated dressings, and
good personal hygiene. Because the risks and benefits of
potential transmission in community settings have yet to
be fully evaluated, patients should be instructed on how
to limit contact with others (family, co-workers, and the
public) if the wound drainage cannot be contained.
PCNPs should conduct a risk assessment on the patients
affected by CA-MRSA. Other sources of potential MRSA
reservoir should also be identified such as athletic facili-
ties or day care centers. Although there are no published
studies on MRSA carriage in pets, there is anecdotal evi-
dence that pets harbored MRSA in recurrent human cases
(Duijkeren et al., 2004; Kim & Del Rossa, 2008; Manian,
2003; Weese et al., 2006). Most of these cases resolved
when the animal was identified as the MRSA carrier and
properly treated by a veterinarian.
Although PCNPs will play a role in educating the pa-
tient and family on proper cleansing of the environment,
there is little research about CA-MRSA to support ap-
proaches to personal hygiene and environmental disin-
fection. Therefore, if a patient or family member has re-
current episodes of CA-MRSA infections or colonization,
a referral should be made to an infectious disease special-
ist (Calfee et al., 2003; Zafar et al., 2007).
Conclusions
Since the discovery of penicillin, antibiotics have saved
lives and reduced suffering. However, bacterial adapta-
tion against antibiotic efficacy has raised new patient
treatment problems. This review demostrates that there
are considerable variations in antibiotic treatment rec-
ommendations for CA-MRSA among experts. As bacte-
rial resistance to common antibiotics continues to evolve,
PCNPs need to stay informed about the most current
recommendations for identification and management of
multidrug-resistant organism infections. Moreover, pa-
tients with any SSTI should be treated conservatively
with I&D of abcesses, warm soaks to the infected area,
and proper wound care regardless of the causative or-
ganism. Such treatment usually resolves infection with-
out increasing antibiotic use.
The incidence and prevalence of CA-MRSA in the
United States is increasing and disease severity varies
from simple, uncomplicated SSTIs to invasive, necrotizing
infections. CA-MRSA causes serious disease in healthier
and younger populations than those currently considered
at risk for HA-MRSA. These trends stimulate ongoing me-
dia attention; the public has more questions and concerns
than ever about antibiotic-resistant bacteria. Because CA-
MRSA infections exhibit symptoms that are similar to
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other types of SA infections, it is impossible to make
the distinction between causative organisms without a
culture and sensitivity. However, empiric treatment in
primary care and outpatient settings may be started while
awaiting results of the culture.
PCNPs will be called upon to treat MRSA infections
and will need a comprehensive understanding of the dif-
ferences and similarities in pathogenicity, diagnosis, and
management of HA-MRSA and CA-MRSA. An additional
purpose of this article was to compare and contrast HA-
MRSA and CA-MRSA treatment and management.
Research on primary care of patients affected by CA-
MRSA in the United States is limited; trends in such re-
search findings and the resulting practice recommenda-
tions from that research will guide primary care prac-
tice. The PCNP is in an important position to address
the care of patients affected by CA-MRSA and should
be knowledgeable about the best research-based methods
and expert recommendations. This knowledge can pro-
mote best practices in treatment and community educa-
tion while helping to reduce transmission of CA-MRSA
among individuals. However, continued research on CA-
MRSA is needed to increase knowledge of the organ-
ism, improve primary care treatment and management of
patients affected by the organism while reducing suffer-
ing, containing healthcare costs, and preventing losses in
productivity.
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